This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Maruyama, S. Articles by Kameyama, M. Search for Related Content PubMed PubMed Citation Articles by Maruyama, S. Articles by Kameyama, M. Social Bookmarking                         What's this?

A Randomized Trial of E5510 versus Aspirin in Patients with Transient Ischemic Attacks

The Japanese E5510 TIA Study-1 (JETS-1) Group

Department of Neurology, Neurological Institute, Tokyo Women's Medical College, Tokyo

Shinichiro Uchiyama

Department of Neurology, Neurological Institute, Tokyo Women's Medical College, Tokyo

Hideo Tohgi

Department of Neurology, Iwate Medical College, Morioka

Shunsaku Hirai

Department of Neurology, Gunma University, Maebashi

Yasuo Ikeda

Department of Internal Medicine, Keio University, Tokyo

Yukito Shinohara

Department of Internal Medicine, Tokai University, Isehara

Tamotsu Matsuda

3rd Internal Medicine Department, Kanazawa University, Kanazawa

Masatoshi Fujishima

2nd Internal Medicine Department, Kyushu University, Fukuoka

Masakuni Kameyama

Sumitomo Hospital, Osaka, Japan

In a randomized double-blind trial, the Study Group compared the efficacy of E5510, a novel antiplatelet agent, and aspirin in preventing the recurrence of transient ischemic attacks (TIA). In total, 227 patients who suffered from TIA in the twelve weeks prior to the study were enrolled. They were randomly allocated to three treatment groups, ie, 71 patients in the E5510 4 mg group, 77 patients in the E5510 2 mg group, and 79 patients in the aspirin 324 mg group, and were treated for twelve to twenty-four weeks. The incidence of recurrent TIA or stroke was 21.5% in the aspirin group and was significantly lower in the E5510 groups, being 8.5% in the 4 mg group (P < 0.05) and 11.7% in the 2 mg group (P < 0.05). Adverse events were observed in 5 cases in the 4 mg group, in 8 cases in the 2 mg group, and in 10 cases in the aspirin group, but none of them were serious. Since safety was judged to be comparable among the three groups, E5510 appears to be an antiplatelet agent for the treatment of TIA with a clinical benefit over aspirin.

Angiology, Vol. 46, No. 11, 999-1008 (1995)
DOI: 10.1177/000331979504601104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?